Veterinary Practice Earnout, Seller Notes & Rollover Equity in 2026

Key takeaways

• The headline price is rarely the cash check. A veterinary practice earnout, a seller note, and rollover equity are the three ways a buyer pays you later instead of now, and each carries a different risk you take on for the privilege.
• Fewer than 60 percent of earnouts pay anything at all across M&A deals, and those that do tend to deliver only a fraction of the maximum, because targets get missed and the buyer controls the operations that determine them. Value cash at close near full and discount the earnout hard.
• A seller note is a loan you make to the buyer — usually 6 to 10 percent interest, three to seven years, almost always subordinated to bank debt and often unsecured. It carries the buyer’s credit risk, not the practice’s.
• Rollover equity is real ownership, but its value lives in the fine print. Where it sits in the capital structure, whether it can defer tax under Section 721, and what minority rights you negotiate matter more than the percentage on the term sheet.
• Structure can swing your take-home substantially on the same headline number. Most vet sellers net somewhere between about 55 and 75 percent of the gross price after taxes, costs, and the cash-versus-deferred split — and the methodology behind the deferred pieces decides where you land, not the multiple everyone fixates on.

There’s a moment in a lot of practice sales where the vet across the table from me is genuinely happy, and I have to be the one to slow it down. The offer came in strong.

The multiple looks great. They’ve already started doing the math on the boat, or the second home, or finally taking the summer off.

And then I ask the question that changes the mood. How much of that number is actually cash at close?

Because on most of the strong offers I see, a meaningful chunk of the headline is not cash. It’s a veterinary practice earnout, or a seller note, or rollover equity, or some blend of all three.

Those are the pieces of the price the buyer pays you later, if they pay you at all, and the terms underneath them decide whether your real outcome matches the number on the letter of intent or falls well short of it.

This article is about that part of the deal. Not what private equity pays for vet practices, which I cover in detail in how much private equity is paying for veterinary practices.

This is the seller-side mechanics of the deferred consideration: how each piece is measured, the specific ways it fails, and what it’s actually worth once you read past the headline.

The short version, so you have it up front: deferred consideration is any part of the sale price you don’t receive as cash at closing — earnouts, seller notes, and rollover equity are the three common forms in veterinary deals. Each one shifts risk from the buyer onto you in exchange for a higher possible number.

Deal structure alone can swing a seller’s net proceeds substantially on the same headline price — two owners with identical multiples can walk away with very different outcomes. So the structure deserves at least as much scrutiny as the multiple, and usually gets far less.

Why the cash-at-close number is the only one I fully trust

When I walk a vet through an offer over dinner, the first thing I do is split the headline into two buckets. Cash at close, and everything else.

Cash at close is money in your account on closing day. Everything else is a promise, and promises in M&A come with conditions, timelines, and counterparties who control the outcome.

That doesn’t make the deferred pieces bad. It makes them worth less than their face value, and the discount is the whole game.

Here’s the pattern I see constantly. A buyer offers a higher headline number that’s heavy on deferred consideration, and a seller hears the big number and stops listening.

A second buyer offers a slightly lower headline that’s heavier on cash, and the seller dismisses it. On paper the first deal looks bigger.

After you discount the earnout for the odds it actually pays, and the rollover for its illiquidity and its place in the capital stack, the second deal is frequently the better one.

That’s why I tell owners to never compare two offers by their headlines. Compare them by risk-adjusted cash, and treat the deferred pieces as what they are: bets with someone else holding the dice.

The three forms of deferred consideration, side by side

Before we go deep on each one, it helps to see them next to each other, because owners blur them together and they are not the same instrument. An earnout is a conditional payment.

A seller note is a loan. Rollover equity is ownership.

Different risks, different protections, different tax treatment.

The table below is the one I’d sketch on a napkin for any vet trying to make sense of a structured offer.

	Earnout	Seller note	Rollover equity
What it is	A payment owed only if post-close targets are hit	A loan you make to the buyer, repaid with interest	A retained ownership stake in the buyer’s entity
Who controls the outcome	The buyer (they run the operations measured)	The buyer’s ability to pay (credit risk)	The platform’s performance and eventual sale
Typical terms	1 to 3 years, most often 2; revenue or EBITDA target	6 to 10 percent interest, 3 to 7 years	Often around 20 percent of proceeds rolled
Security / priority	Unsecured obligation of the buyer	Usually subordinated to bank debt, often unsecured	Depends on preferred vs common; often junior
Tax at close	Taxed when received	Interest taxed as earned; principal as received	Can defer under Section 721 if structured right
Main risk	Targets missed; under 60% pay anything, and partly	Buyer defaults; little collateral to recover	Illiquid; payout below face if platform underperforms

Every cell in that table is a negotiation, and every one of them moves your real number. Now let’s take them one at a time.

How a veterinary practice earnout actually works, and how it fails

An earnout is part of the sale price paid later, and only if the practice hits agreed performance targets after closing. In veterinary deals these typically run 1 to 3 years, with the 2-year mark showing up most often, and they’re increasingly measured as a multiple of the increase in revenue, or more often EBITDA, between closing and the end of the earnout period (DVM Evolution).

EBITDA, if it’s new to you, is what your practice earns in pure operating profit before taxes and accounting choices.

The structure is simple enough to describe in a sentence. The buyer says: we’ll pay you more if the practice grows, and the earnout is the mechanism that delivers that extra money when the growth shows up.

The problem is everything underneath that sentence.

Start with the headline risk. Across M&A deals, data from SRS Acquiom shows that fewer than 60 percent of earnouts result in any payment at all, and among those that do pay, the average comes out to only around a fifth of the maximum potential (SRS Acquiom).

Outcomes vary widely by deal, but the direction is clear, and it should reframe how you read any earnout on a term sheet. A large share of the stated number, more often than not, never arrives.

Why does so much of it evaporate? Four reasons, and only one of them is the seller’s fault.

Legitimate underperformance, yes. But also buyer-controlled costs, measurement disputes, and caps that quietly limit the upside even when you do hit the targets.

The deepest issue is structural, and it’s worth understanding because it explains the rest. An earnout separates risk from control.

You carry the risk that the targets get missed, but operational control has shifted to the buyer at closing, and the buyer is the one who reports the metrics the payment depends on (Kroll). A buyer who owes you money based on numbers they calculate has limited incentive to maximize what they owe you.

That isn’t a knock on any particular buyer. It’s the math of the structure, and it’s the single most common source of post-closing disputes in M&A generally.

This is also why the measurement basis matters more than almost anything else in the clause. A revenue-based target is much harder for a buyer to move than an EBITDA-based one.

A buyer with operational control can shift expenses, overspend on marketing, or charge shared-services, overhead, and management fees to the acquired unit, all of which push EBITDA down without anyone doing anything improper. Revenue is far cleaner, because the seller, especially one still working in the practice, has more direct influence over it and it’s harder to manipulate from the buyer’s side.

Every earnout is subject to some gamesmanship. The gap between revenue-based and EBITDA-based is a gap of degree, and the degree is large.

So if you can’t avoid an earnout, the things to negotiate are clear: tie it to revenue rather than EBITDA where you can, define every input precisely, cap the buyer’s ability to load costs onto the practice, secure audit rights over the metrics, and shorten the period. A 4-year EBITDA earnout with vague definitions is a very different instrument than a 1-year revenue earnout with tight definitions, even at the same dollar figure.

Seller notes: you’ve just become the bank, usually an unsecured one

The second form of deferred consideration gets the least attention and carries a risk owners rarely price correctly. A seller note is a loan you effectively make to the buyer, where part of the price is paid over time with interest instead of cash at closing.

The terms have a recognizable shape. Seller notes commonly carry an interest rate of roughly 6 to 10 percent, above the 4 to 5 percent on senior bank debt because they sit in a riskier position, and they usually mature over three to seven years, often as a five-year note carrying current interest (Hadley Capital).

On the surface that looks fine. You’re getting paid, with interest, for waiting.

The risk is in the priority and the security, not the rate.

Here’s the part that matters. Seller notes are almost always subordinated to the buyer’s senior bank debt, and most are unsecured. Subordination means your note sits behind the bank in line to get paid — the repayment order runs senior debt first, then your seller note, then equity.

Unsecured means there’s no specific collateral you can seize if the buyer stops paying.

Put those two facts together and the exposure is obvious. If the practice struggles under its new owner, the bank gets made whole before you see another dollar, and if there’s nothing left after the bank, there may be no collateral to recover against at all (Hadley Capital).

You’re carrying the buyer’s credit risk, in a junior position, frequently with no security. That’s a very different thing from “the rest of my money, paid over five years.”

The subordination terms themselves are negotiable, and they’re where a good advisor earns the fee. Standstill provisions and payment-blockage rights — the lender’s ability to stop the buyer from paying you while the senior loan is stressed — vary deal to deal.

So does whether any part of the note can be secured. A note isn’t simply good or bad.

A short, partially secured note with tight blockage limits from a well-capitalized buyer is a reasonable instrument. A long, fully subordinated, unsecured note from a thinly capitalized buyer is a coin flip you’re calling for them.

Rollover equity: the second bite, and what it’s really worth

Rollover equity is the piece owners are most excited about and understand the least. Rollover equity means keeping a slice of ownership in the buyer’s acquiring or platform entity instead of taking all of your proceeds in cash at close.

The appeal is real. PE-backed veterinary buyers commonly ask sellers to roll roughly 10 to 40 percent of their proceeds into equity of the acquiring entity, with around 20 percent a standard target, trading immediate cash for a retained stake and a shot at what the industry calls the “second bite of the apple” (Mahan Law).

The second bite is the idea that when the platform you rolled into gets sold a few years later at a higher multiple, your retained slice pays out again, sometimes for more than your original cash would have been. That’s the dream version, and it does happen.

There’s a genuine tax advantage layered on top, and it’s worth getting right. Rollover equity can often be structured to defer tax under IRC Section 721 — contributing your equity into a buyer-controlled partnership or LLC in exchange for an interest is generally a nonrecognition event, so the tax on the rolled portion is deferred, not forgiven, until a future sale (Cordasco & Company).

The cash portion of your proceeds is still taxed at close. The catch is that the deferral requires the deal to be structured correctly and can be lost to rules like the disguised-sale provisions, which is exactly the kind of thing you confirm with a tax advisor before you sign, not after.

For how the rest of your proceeds get taxed, the tax consequences of selling a veterinary practice page goes deeper.

Now the part that gets skipped, and the part that decides whether your rollover is worth anything close to its face value. It all comes down to where the equity sits in the capital structure.

Rolling into preferred stock that ranks alongside the sponsor is significantly safer than rolling into common stock that sits below the sponsor’s preferred (Auxo Capital Advisors). The reason is the liquidation preference — a right held by preferred equity to be paid first, ahead of common equity, when the entity is sold.

A common preference is around 1x the invested amount plus a preferred return. If your rolled equity is common stock sitting underneath a preferred stack with a liquidation preference, and the platform later sells at a lower multiple than everyone projected, the preferred holders get paid first and your common slice can pay out less than its stated face value.

Same percentage on the term sheet, very different real outcome.

This is why I tell owners the rollover percentage is almost the least important term in the rollover. What you want to know is: am I rolling into preferred or common?

Is there a liquidation preference ahead of me, and how big? And what does the operating agreement actually say about my rights as a minority holder?

On that last question, three protections matter most. Tag-along rights let you sell your stake alongside the sponsor if they sell, so you’re not stranded. Drag-along rights let the majority force you into a sale, which protects the buyer, not you. And exit ratchets adjust who gets what at the finish line.

Tag-along protects the minority seller; drag-along protects the majority buyer (Axial). For a minority rollover holder, those rights often matter more than the nominal ownership percentage, because they decide whether you can actually get your money out and on what terms.

And you can’t get it out quickly regardless. Rolled equity is illiquid and speculative.

You’re locked in until a future liquidity event that, on the PE side, is often open-ended, and the return is not guaranteed (Acquisition Stars). The counter, when you have the leverage to push for it, is to negotiate the lockup window down and tie your liquidity to defined milestones — a 5-year mark, a sponsor-led recapitalization, a specified exit — rather than waiting open-endedly on the platform’s eventual sale.

I should name the alternative that’s become common, because it solves several of these problems at once. A growing number of PE-backed vet buyers now use a partnership or joint-venture structure, where you retain direct equity in your own practice rather than platform-level equity, with a contractual put or call that guarantees liquidity at a defined future date, usually around 5 years, often at a formula-based multiple.

The distinction is real: a true JV stake in your own practice, with a defined exit and distributions along the way, is a different risk profile than common rollover into a platform you don’t control. Which one is on the table is one of the first things I want to understand about any structured offer.

Earnout versus rollover equity: if you have to pick

Owners often ask me which is better, an earnout or rollover equity, as if it’s a clean choice. Sometimes it is, and when it is, I have a preference.

Many sell-side advisors, myself included, lean toward rollover over an earnout when forced to choose (Founder M&A). The logic is straightforward.

An earnout pays only if post-close targets are hit, and those targets depend on operations the buyer now controls and metrics the buyer reports. Rollover equity gives you genuine ongoing ownership, real participation in the upside, rather than a contingent promise tied to numbers calculated on the other side of the table.

But the choice often isn’t yours. Large strategic buyers are frequently reluctant to hand out equity in their parent entity, so they lean on earnouts and notes instead.

PE-backed platforms usually prefer and offer rollover, because getting the selling vet to retain a stake aligns everyone’s incentives for the hold period. So the form of deferred consideration on your term sheet tells you something about who the buyer is and how they think, before you’ve negotiated a single term.

The deeper point is that the buyer’s identity and the structure they default to are tied together, which is one more reason to get multiple types of buyers to the table. A field of qualified bidders gives you offers across the structural spectrum, and the comparison between them is where you learn what your practice is actually worth in cash terms.

If you want to understand the buyer landscape first, the veterinary practice consolidators directory lays out who’s active in 2026.

What the structure does to your actual take-home

Let me bring this back to the only number that matters, which is what ends up in your account over time.

Most vet sellers net somewhere between about 55 and 75 percent of the gross sale price after taxes, transaction costs, debt payoff, and the cash-versus-deferred split. Sit with that for a second.

Two owners can sign offers with identical headline multiples and walk away with materially different outcomes, purely on structure.

The earnout methodology, the working-capital calculation, and the rollover terms drive your take-home far more than the top-line multiple does. That’s not how most owners think about an offer, and it’s the single most expensive misunderstanding I see.

There’s a subtler point hiding in the rollover math too. If you retain, say, 30 percent of your practice as rollover or JV equity, the buyer is economically purchasing only about 70 percent of the practice’s future financial performance — you still own a third of whatever happens next, for better or worse.

And every earnout obligation is an unsecured obligation of the buyer, which means it carries the buyer’s credit risk, not the practice’s. The strength of the entity standing behind these promises is part of the price, even though it never appears on the term sheet.

This is the whole reason the valuation of your veterinary practice can’t stop at a multiple. A real valuation has to account for how the price gets paid, because the payment structure is where a strong-looking number quietly becomes an ordinary one, or an ordinary-looking number becomes a strong one.

How a competitive process protects the structure, not just the price

Most of what I’ve described is harder to fix once you’re sitting across from a single buyer in exclusivity. By then the structure is largely whatever they propose, because you have no credible alternative and they know it.

This is where the way we run a sale earns its keep. The methodology we use is the Elite Selling System — we hand-select and vet every buyer who gets to bid on your practice, the way a doorman with a velvet rope lets in only the right people, and then we run a private competitive window inside that vetted group.

People focus on what that does to the headline number. What gets underrated is what it does to the structure.

When several qualified buyers are competing, the terms move, not just the price. The cash-at-close share goes up.

The earnout shrinks or shifts to a cleaner revenue measurement. The seller note gets shorter or partially secured.

The rollover gets repriced into a safer slice of the capital structure with better minority rights. None of that happens reliably in a single-bidder negotiation, because a lone buyer has no reason to improve terms they’ve already gotten you to accept.

Structure is leverage made visible. A prepared seller with real competition keeps not only their number but the shape of how that number gets paid, and the shape is where the risk lives.

What to do next

If you take one thing from all of this, let it be that you cannot evaluate a veterinary practice offer by its headline. The deferred pieces — the earnout, the note, the rollover — are where the real outcome is decided, and each one is a set of terms you can negotiate or lose by default.

If you’re inside the window before a sale, the highest-value moves are to understand the structure before you fall in love with the number, to insist on cleaner earnout measurement and a safer rollover position, and above all to make sure you have more than one qualified buyer at the table so the structure is competitive and not dictated. The order matters too — get sale-ready first, which the guide to selling a veterinary practice walks through end to end.

Get a Free Practice Value Estimate →

We pull your numbers, build a defensible valuation, and then model what each piece of a structured offer is actually worth to you on a risk-adjusted basis, so you’re comparing real outcomes and not headlines. Then we identify the right group of qualified buyers for your specific profile and run a competitive process that moves both the number and the structure in your favor.

The estimate is free and there’s no obligation to engage further. The Transitions Elite engagement model is success-based, with no upfront fees and no retainer, so we only get paid when a deal closes and only out of the value our process protects and delivers.

---

Further reading

These are the related TE resources I’d point any vet toward as they think through a structured offer. Each goes deep on a single piece of the decision.

• How much private equity is paying for veterinary practices — the four components of a PE-backed offer and why the headline rarely equals the cash check.
• Veterinary practice EBITDA multiples — what practices actually sell for in 2026, by size and by sale process.
• How to sell a veterinary practice — the full process from advisor engagement to closing.
• Veterinary practice due diligence — what a buyer’s team scrutinizes after the letter of intent, and how to keep the price you were promised.
• Tax consequences of selling a veterinary practice — how the cash and the deferred pieces get taxed differently.
• Valuate a veterinary practice — how value is built before structure ever enters the conversation.
• Sell my veterinary practice — the owner’s decision guide to your sale paths in 2026.

Frequently asked questions

What is an earnout in a veterinary practice sale?

An earnout is part of the sale price paid later, and only if the practice hits agreed performance targets after closing. In veterinary deals these typically run 1 to 3 years, most often 2, and are measured against a revenue or EBITDA increase between closing and the end of the period.

The seller carries the risk while the buyer controls operations, which is why across M&A deals fewer than 60 percent of earnouts pay anything at all, and those that do tend to deliver only a fraction of the maximum. A revenue-based target is generally harder to depress than an EBITDA-based one.

What is rollover equity in a veterinary practice sale?

Rollover equity means keeping a slice of ownership in the buyer’s acquiring or platform entity instead of taking all of your proceeds in cash. PE-backed veterinary buyers commonly ask sellers to roll roughly 10 to 40 percent of proceeds, with around 20 percent a typical target.

It can be structured to defer tax under IRC Section 721, and it offers a potential second payout when the platform is later sold, but it is illiquid and its real value depends on where it sits in the capital structure.

What is the difference between an earnout and rollover equity?

An earnout pays the seller only if post-close performance targets are hit, and those targets depend on operations the buyer now controls. Rollover equity gives the seller genuine ongoing ownership that pays out when the buyer’s entity is later sold.

Many sell-side advisors prefer rollover over an earnout when forced to choose, because a rollover is real ownership rather than a contingent promise tied to metrics the buyer reports. The seller does not always get to choose, since large strategic buyers are often reluctant to give equity while PE-backed platforms usually prefer to offer it.

What percentage of an earnout actually gets paid?

Across M&A deals, data from SRS Acquiom indicates that fewer than 60 percent of earnouts result in any payment at all, and among those that do pay, the average works out to only around a fifth of the maximum potential. Targets get missed through legitimate underperformance, buyer-controlled costs, measurement disputes, and caps that limit the upside.

Outcomes vary widely by deal, but the takeaway holds: a seller should value the cash at close near full and discount the earnout heavily. The structure of the measurement, especially revenue versus EBITDA, drives how much of it survives.

How does a seller note work when selling a veterinary practice?

A seller note is a loan the seller effectively makes to the buyer: part of the price is paid over time with interest instead of cash at closing. Industry terms commonly run a 6 to 10 percent interest rate, above the 4 to 5 percent on senior bank debt, with a three to seven year maturity, often a five-year note.

Seller notes are almost always subordinated to the buyer’s senior bank debt and most are unsecured, so if the practice fails there may be little to recover against. Terms are highly negotiable.

Is rollover equity in a veterinary practice worth it?

It depends almost entirely on where the rolled equity sits in the capital structure and how liquid it is. Rolling into preferred stock that ranks alongside the sponsor is meaningfully safer than rolling into common stock that sits below the sponsor’s preferred, where a liquidation preference can mean a payout below face value if the platform sells for less than projected.

Rolled equity is illiquid and speculative, with no guaranteed return, so the protections that matter are tag-along rights, a negotiated liquidity window, and clear minority rights in the operating agreement.

Is rollover equity taxed when you sell a veterinary practice?

Rollover equity can often be structured to defer tax under IRC Section 721. Contributing equity into a buyer-controlled partnership or LLC in exchange for an interest is generally a nonrecognition event, so tax on the rolled portion is deferred, not forgiven, until a future sale.

The cash portion of your proceeds is still taxed at close. Section 721 treatment requires the deal to be structured correctly and the deferral can be lost, so this is something to confirm with a tax advisor rather than assume.

How much of a veterinary practice sale is paid in cash at closing?

It varies by buyer and deal, but the headline price is rarely all cash. Most vet sellers net between about 55 and 75 percent of the gross sale price after taxes, costs, debt payoff, and the cash-versus-deferred split, and deal structure alone can swing that net proceeds figure substantially on the same headline number.

The earnout methodology, working-capital calculation, and rollover terms drive take-home pay more than the top-line multiple does, which is why the structure deserves as much scrutiny as the number.

---

Sources

Industry M&A research, deal structure, and valuation data

1. DVM Evolution. “Veterinary Practice Purchase Price Consideration: Earn Outs.” dvmevolution.com
2. SRS Acquiom. “Managing M&A Earnouts: Everything You Need to Know.” srsacquiom.com
3. Kroll. “Earn-Outs in M&A: Key Deal Tool or Source of Post-Closing Disputes?” kroll.com
4. Hadley Capital. “Seller Notes: What They Are and How They Work.” hadleycapital.com

Rollover equity, capital structure, and minority-holder terms

6. Mahan Law. “Rollover Equity Attorney for Veterinarians.” mahanlaw.com
7. Auxo Capital Advisors. “Rollover Equity in M&A: Terms, Taxes & Pitfalls.” auxocapitaladvisors.com
8. Axial. “Rollover Equity: A Business Owner’s Guide to Negotiating Terms.” axial.net
9. Acquisition Stars. “Rollover Equity in M&A: How Sellers Retain Upside After Close.” acquisitionstars.com
10. Founder M&A. “Earn-Outs vs. Rolled Equity vs. Seller Notes Explained.” founderma.com

Tax analysis

11. Cordasco & Company. “Section 721: The Tax-Deferred Powerhouse Every M&A Player Needs to Understand.” 2026. cspcpa.com